Warfarin is prescribed for:
Warfarin is an anticoagulant (blood thinner) that works by blocking the production of vitamin K-dependent clotting factors in the body, specifically Factors II, VII, IX, and X. The blood-thinning effect usually starts within 24 hours of taking the medication. This effect peaks between 36 to 48 hours and can last for 48 hours or more after the last dose.
Warfarin is a vitamin K antagonist. It works by inhibiting the enzyme vitamin K epoxide reductase, which is essential for recycling vitamin K in the body. The active form of vitamin K acts as a cofactor that enables the γ-carboxylation (activation) of clotting factors II (thrombin), VII, IX, and X. This carboxylation process allows these factors to bind to calcium and phospholipid surfaces, which is necessary for forming a clot. Without this modification, these clotting factors remain inactive, effectively interrupting the blood coagulation cascade. The natural anticoagulant proteins C and S also require this process to function properly. During the carboxylation reaction, active vitamin K is converted into vitamin K epoxide. Normally, the enzyme vitamin K epoxide reductase recycles this epoxide back into its active form. Warfarin blocks this enzyme, preventing the recycling process. As a result, the body runs out of active vitamin K, leading to the production of inactive clotting factors. When warfarin therapy begins, there is a temporary hypercoagulable (increased clotting risk) state because the natural anticoagulant proteins C and S degrade faster than some clotting factors. Proteins C and S have short half-lives (8 and 24 hours, respectively), and factor VII (which also has a short half-life of 6 hours) degrades quickly. However, factors IX, X, and thrombin degrade much more slowly, with half-lives of 24, 36, and 50 hours. This delay means that for a short time, the body has less protection against clotting while most clotting factors are still present, before the full anticoagulant effect takes over.To reverse warfarin's effects, vitamin K must be supplied (either through diet, supplements, or by allowing the body to resume production) so that the liver can synthesize new, functional clotting factors. This synthesis typically takes about two days.Additionally, vitamin K₂ (which is functionally similar to vitamin K₁) is produced by bacteria in the gut. This is why antibiotics can interact with warfarin; they may kill these bacteria, reducing vitamin K levels and potentially enhancing warfarin's effect.
A baseline prothrombin time test should be done whenever possible, but treatment should not be delayed while waiting for the result.
Use in adults: The usual starting (induction) dose for adults is 10 mg daily for the first 2 days. The ongoing maintenance dose is then adjusted based on the prothrombin time, which is reported as the INR (International Normalized Ratio). The typical daily maintenance dose ranges from 3 to 9 mg and should be taken at the same time each day. If the INR becomes too high (prothrombin time excessively prolonged), the maintenance dose should be skipped. Once a stable dose within the therapeutic range is established, it rarely needs to be changed. In emergency situations, anticoagulation should be started with both heparin and warfarin together. In less urgent cases—such as for patients at high risk of thromboembolism—treatment may be started with warfarin alone. Regular monitoring tests are required, and the maintenance dose should be adjusted based on the results.
Use in children: The safety and effectiveness of warfarin in children under 18 years have not been formally established. However, there is clinical evidence supporting its use; the typical starting dose is 0.1 mg/kg/day, adjusted to achieve an INR range similar to that used for adults.
Oral anticoagulants like warfarin have a high potential for clinically significant interactions with other medications. Patients should be warned about these potential risks and instructed not to take or stop any drug—including over-the-counter (non-prescription) products—without first consulting their doctor.
Warfarin should not be used in the following cases:
Additionally, caution is required when using warfarin within 24 hours after surgery or childbirth; in such cases, it should only be used if absolutely necessary.
Hemorrhage is the primary adverse effect of oral anticoagulants. Other reported side effects include nausea, vomiting, diarrhea, hypersensitivity reactions, rash, hair loss (alopecia), unexplained decrease in hematocrit, “purple toes” syndrome, skin necrosis, jaundice, and liver dysfunction.
Warfarin is contraindicated during the first trimester of pregnancy due to the risk of teratogenicity. It should not be used in women who are pregnant or may become pregnant, as it crosses the placental barrier and may cause fatal bleeding in the fetus. Warfarin is excreted into breast milk in an inactive form. Infants breastfed by mothers receiving Warfarin have not shown changes in prothrombin time. The effects in premature infants have not been evaluated.
Regular monitoring of prothrombin time (PT)/international normalized ratio (INR) or other appropriate coagulation tests is essential. Various factors such as travel, dietary changes, environmental conditions, physical status, and concomitant medications may influence the patient’s response to anticoagulants. It is advisable to monitor PT/INR more frequently after hospital discharge and whenever medications are started, stopped, or taken irregularly. Certain conditions may enhance the effect of warfarin and require dose reduction, including weight loss, advanced age, acute illness, impaired renal function, reduced vitamin K intake, and use of interacting drugs. Conversely, factors such as weight gain, diarrhea, vomiting, increased intake of vitamin K, fats and oils, and use of certain medications may necessitate an increase in the maintenance dose. If switching between formulations, careful laboratory monitoring is required. Reversal of warfarin’s anticoagulant effect with vitamin K may take several days. In emergency situations, fresh frozen plasma should be administered.
If bleeding occurs or there is a risk of bleeding due to excessive anticoagulation, the condition can be corrected by temporarily stopping warfarin. In more serious cases, this may be accompanied by an infusion of fresh-frozen plasma or whole blood to replace clotting factors. Additionally, vitamin K (5 mg to 10 mg given orally or intravenously) may be needed to support treatment, particularly when using clotting factor concentrates.
Anticoagulants (Blood thinners) / Oral Anticoagulants
Do not store above 30°C. Protect from light and keep out of reach of children.
How does warfarin work?
What is warfarin used for?
How should I take warfarin?
Can I take warfarin during pregnancy?
How should I store warfarin?
